deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT05319028

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 Study of Mivavotinib in Biomarker-Defined Subgroups of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Sponsor: Calithera Biosciences, Inc

Conditions Non-GCB/ABC Diffuse Large B-Cell Lymphoma With and Without MyD88 and/or CD79B Mutations
Interventions Mivavotinib
Updated 9 times since 2022 Last updated: Mar 31, 2023 Started: Jun 23, 2022 Primary completion: Feb 24, 2023 Completion: Feb 24, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor Decision

Other terminated trials from Calithera Biosciences, Inc

More terminations from Calithera Biosciences, Inc

A PHASE2 clinical study on Non-GCB/ABC Diffuse Large B-Cell Lymphoma and With and Without MyD88 and/or CD79B Mutations, this trial is terminated or withdrawn. The trial is conducted by Calithera Biosciences, Inc and has accumulated 9 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2022 – ~Jul 2022 · 2 months · monthly snapshotNot Yet Recruiting~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshotRecruiting~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshotRecruiting~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshotRecruiting~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotRecruiting~Jan 2023 – ~May 2023 · 4 months · monthly snapshotRecruiting~May 2023 – ~Jul 2024 · 14 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. May 2023 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  4. Jan 2023 — May 2023 [monthly]

    Recruiting PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

▶ Show 4 earlier versions

  1. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  2. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  3. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  4. May 2022 — Jul 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Calithera Biosciences, Inc
Data source: Calithera Biosciences, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations